Abstract
AbstractThe cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic compounds in the environment. The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug–drug interactions. This review presents a comprehensive update on the inhibitors and inducers of the specific CYP enzymes in humans. The focus is on the more recent human in vitro and in vivo findings since the publication of our previous review on this topic in 2008. In addition to the general presentation of inhibitory drugs and inducers of human CYP enzymes by drugs, herbal remedies, and toxic compounds, an in-depth view on tyrosine-kinase inhibitors and antiretroviral HIV medications as victims and perpetrators of drug–drug interactions is provided as examples of the current trends in the field. Also, a concise overview of the mechanisms of CYP induction is presented to aid the understanding of the induction phenomena.
Funder
Academy of Finland
Suomen Lääketieteen Säätiö
Sydäntutkimussäätiö
Pohjois-Suomen Terveydenhuollon Tukisäätiö
Diabetestutkimussäätiö
University of Oulu including Oulu University Hospital
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology,General Medicine
Reference555 articles.
1. Abbas R, Hsyu P (2016) Clinical pharmacokinetics and pharmacodynamics of bosutinib. Clin Pharmacokinet 55:1191–1204
2. Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D (2012) Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects. Clin Ther 34:2011–2019.e1
3. Abbas R, Boni J, Sonnichsen D (2015) Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects. Drug Metab Pers Ther 30:57–63
4. Abel S, Back DJ, Vourvahis M (2009) Maraviroc: pharmacokinetics and drug interactions. Antivir Ther (Lond) 14:607–618
5. Abraham K, Geusau A, Tosun Y, Helge H, Bauer S, Brockmoller J (2002) Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction. Clin Pharmacol Ther 72:163–174
Cited by
211 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献